HomeLarge Type Edition
HOME ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
PubMed
Right arrow PubMed Citation
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56:B311-B323 (2001)
© 2001 The Gerontological Society of America

Melatonin Increases Both Life Span and Tumor Incidence in Female CBA Mice

Vladimir N. Anisimova, Natalia Y. Zavarzinaa, Mark A. Zabezhinskia, Irina G. Popovicha, Olga A. Ziminac, Anastasia V. Shtylickb, Alexander V. Arutjunyanc, Tatiana I. Oparinac, Valentina M. Prokopenkoc, Anatoli I. Mikhalskid and Anatoli I. Yashine

a N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
b St. Petersburg State University, St. Petersburg, Russia
c D. O. Ott Research Institute of Obstetrics and Gynecology, St. Petersburg, Russia
d Institute of Control Sciences of the Russian Academy of Sciences, Moscow, Russia
e Max-Planck Institute for Demographic Research, Rostock, Germany

Vladimir N. Anisimov, Laboratory of Carcinogenesis and Aging, N. N. Petrov Research Institute of Oncology, Pesochny-2, St. Petersburg 197758, Russia E-mail: aging{at}mail.ru.

Decision Editor: John Faulkner, PhD

From the age of 6 months until their natural deaths, female CBA mice were given melatonin with their drinking water (20 mg/l) for 5 consecutive days every month. Intact mice served as controls. The results of this study show that the consumption of melatonin did not significantly influence food consumption, but it did increase the body weight of older mice; it did not influence physical strength or the presence of fatigue; it decreased locomotor activity and body temperature; it inhibited free radical processes in serum, brain, and liver; it slowed down the age-related switching-off of estrous function; and it increased life span. However, we also found that treatment with the used dose of melatonin increased spontaneous tumor incidence in mice. For this reason, we concluded that it would be premature to recommend melatonin as a geroprotector for long-term use.




This article has been cited by other articles:


Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
V. Molpeceres, J. L. Mauriz, M. V. Garcia-Mediavilla, P. Gonzalez, J. P. Barrio, and J. Gonzalez-Gallego
Melatonin Is Able to Reduce the Apoptotic Liver Changes Induced by Aging Via Inhibition of the Intrinsic Pathway of Apoptosis
J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2007; 62(7): 687 - 695.
[Abstract] [Full Text] [PDF]

Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
R. N. Butler, M. Fossel, S. M. Harman, C. B. Heward, S. J. Olshansky, T. T. Perls, D. J. Rothman, S. M. Rothman, H. R. Warner, M. D. West, et al.
Is There an Antiaging Medicine?
J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2002; 57(9): B333 - 338.
[Abstract] [Full Text] [PDF]


HOME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by The Gerontological Society of America.